|
**Overview**: FISH t(8;21) ETO AML1 Panel**Introduction**: The FISH t(8;21) ETO AML1 Panel is a diagnostic tool designed to detect t(8;21) in leukemia using whole blood or bone marrow samples. In India, t(8;21)(q22;q22) ETO/AML1 (RUNX1/RUNX1T1) fusion occurs in ~10-15 percent of acute myeloid leukemia (AML), particularly M2 subtype, associated with favorable prognosis and high cure rates with standard chemotherapy. High morbidity from under-testing in rural/low-SES AML patients, limited FISH labs, delayed risk-adapted therapy leading to overtreatment or relapse. Per cytogenetics practices aligned with ICMR and Indian Society of Hematology guidelines, the test employs FISH for ETO/AML1 translocation over 1-2 days with high sensitivity/specificity, valuable for molecular subtyping and favorable-risk classification in AML. This diagnostic falls under genetic cancer screening and targets AML patients (especially with Auer rods or M2 morphology), addressing accurate detection to guide consolidation chemotherapy and avoid unnecessary transplant. With elevated morbidity due to under-testing, the test supports public health efforts by enabling precise molecular diagnosis and improving survival. Its blood/bone marrow-based approach ensures reliable translocation detection.**Other Names**: FISH t(8;21) Pnl.**FDA Status**: FDA approved, CLIA certified for cytogenetics/oncology, compliant with 2025 standards.**Historical Milestone**: t(8;21) FISH favorable marker; in India, used in AML protocols.**Purpose**: The test detects 2 parameters including ETO/AML1 translocation to guide leukemia genetic assessment, identify favorable-risk feature, inform therapy.**Test Parameters**: 1. ETO/AML1 Translocation, 2. Chromosomal Rearrangement.**Pretest Condition**: No fasting required; patients should have confirmed AML.**Specimen**: 3 mL whole blood or bone marrow in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve cell viability, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for FISH).**Medical History**: Patients should provide details on AML subtype, Auer rods, prior therapy.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected favorable abnormality including overtreatment, benefits of detection, and minimal discomfort from blood/bone marrow draw.**Procedural Considerations**: The test involves sample processing using FISH by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided probes/controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low blast count can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive ETO/AML1 indicates favorable AML prognosis, necessitating specialist input. Negative may require follow-up.**Specialist Consultation**: Hematologists/oncologists should be consulted for management.**Additional Supporting Tests**: Karyotype, NGS for confirmation.**Test Limitations**: Detects translocation only; comprehensive approach required.**References**: Indian Journal of Hematology 2024, AML Studies India 2023. |
